Why Telomir Pharmaceuticals, Inc.’s (TELO) Stock Is Down 15.93%
As of Tuesday, November 10, Telomir Pharmaceuticals, Inc.’s TELO share price has dipped by 15.93%, which has investors questioning if this is right time to buy.Rosalio Madrigal
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Michael Rose
Jenna Brashear
Michael Rose
Cynthia McLaughlin
| Share Statistics | TELO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $26.8 | $421.5 | 13% |
|
| Shares Out (Mil) | 68.8 | 46.9 | 54% |
|
| Institutional Ownership | 18.7% | 82.0% | 9% |
|
| Float (Mil) | 42.0 | 49.2 | 43% |
|
| Beta | -0.19 | 0.68 | 3% |
|
| Avg Daily Volume (000s) | 274 | 347 | 49% |
|
| Price Change (52-week) |
(74.6%) | 49.3% | 12% |
|
| Growth | TELO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.4% | na |
|
| Net Income (5yr) | na | (1.3%) | na |
|
| EPS (5yr) | na | 15.1% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | TELO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $275 | na |
|
| Net Income (TTM) (Mil) | ($6) | ($11) | 32% |
|
| EPS (TTM) | ($1.043) | ($0.700) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($5) | ($7) | 26% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $32 | $331 | 15% |
|
| Valuation | TELO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.07 | 2.08 | 86% |
|
| P/E | na | 20.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | TELO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.5% | na |
|
| Net Margin | na | 3.6% | na |
|
| ROA | (91.0%) | (23.8%) | 6% |
|
| ROE | (96.3%) | (24.2%) | 9% |
|
| Liabilities to Assets | 5.1% | 31.6% | 2% |
|
| F-Score | 3 | 3 | 18% |
|
Telomir Pharmaceuticals, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors